Search the Newsreel

PureCycle Technologies (PCT) corrects CFO Carpenter’s reported share holdings

PureCycle Technologies (PCT) has filed an amended insider ownership report (Form 3/A) for its Chief Financial Officer, Donald Carpenter. The amendment corrects a previous clerical error, clarifying that Carpenter directly holds 136,895 shares of Common Stock as of March 1, 2026. This filing updates …

PureCycle Schedules Second Quarter 2026 Corporate Update

PureCycle Technologies, Inc. announced it will host a conference call on Thursday, August 6, 2026, to provide a corporate update on recent developments and activities from the second quarter of 2026. A press release detailing these developments will precede the call. The company specializes …

PureCycle กำหนดการรายงานข้อมูลอัปเดตของบริษัทประจำไตรมาสที่ 2 ปี 2026

PureCycle Technologies, Inc. (NASDAQ: PCT) will host its second-quarter 2026 corporate update conference call on Thursday, August 8, 2026, at 11:00 AM Eastern Time. The update will provide details on the company's progress and financial results. Investors and interested parties can access the webcast …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Unicycive Therapeutics, Inc. (UNCY) following a significant drop in its stock price. This investigation comes after the FDA issued a second Complete Response Letter regarding the company's kidney disease therapy, oxylanthanum, citing unresolved third-party …

Unicycive Therapeutics (NASDAQ:UNCY) Downgraded to Strong Sell Rating by Zacks Research

Cycliq Returns to Positive Operating Cash Flow in Q4 FY2026 as End of Financial Year Campaign Drives Sales Momentum

Cycliq Group Lifts Operating Cash Position to $536,000 in June Quarter as Revenue Grows

Cycurion, Inc. Announces Scheduled Nasdaq Listing Hearing and Reaffirms Commitment to Maintaining Nasdaq Listing

MCLEAN, Va., July 22, 2026 (GLOBE NEWSWIRE) -- Cycurion, Inc. (NASDAQ: CYCU) ("Cycurion" or the "Company"), a leading AI-driven, tech-enabled cybersecurity solutions provider, today announced that, as planned and previously disclosed, it requested a hearing before the Nasdaq Hearings Panel (the "Panel") to appeal …

Pure Cycle Corporation (PCYO) Q2 2026 Earnings: Profitability Achieved with EPS of $0.12 Amidst Limited Revenue Disclosure - Earnings Outlook Update

PCT stock trades on Nasdaq as PureCycle reports widening losses and advances recycling capacity

PureCycle Technologies Inc. (PCT) is trading on Nasdaq, with its stock reflecting the company's efforts to commercialize polypropylene recycling. While PureCycle has seen revenue growth from a near-zero base, it continues to report widening net losses as it invests heavily in building its first …

Form 13D/A CYCLERION THERAPEUTICS For: 21 July By Investing.com

This article announces the filing of a Form 13D/A for Cyclerion Therapeutics (CYCN) on July 21. It is a brief, technical update from Investing.com, typical of financial news reporting on SEC filings. The article itself contains no additional commentary or details beyond the filing …

Cyclerion Therapeutics (CYCN) investor reports 19.4% stake and preferred share conversion

Peter M. Hecht has updated his beneficial ownership in Cyclerion Therapeutics, Inc. (CYCN), now holding 910,240 shares of Common Stock, representing 19.4% of the outstanding class. This change resulted from the forfeiture of options for 110,984 shares and the conversion of 351,037 non-voting Series …

Cyclerion Therapeutics (CYCN) director converts 351,037 preferred to common shares

Cyclerion Therapeutics director Peter M. Hecht converted 351,037 shares of Series A Convertible Preferred Stock into an equal number of Common Stock shares on July 16, 2026, eliminating all his preferred holdings. This transaction increased his direct common stock ownership to 910,240 shares, and …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating Unicycive Therapeutics, Inc. (UNCY) after the FDA issued a second Complete Response Letter for its kidney disease therapy, oxylanthanum, citing unresolved manufacturing deficiencies. The law firm is encouraging investors who purchased Unicycive securities to join their investigation …

PCT5917096 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the PureCycle Technologies, Inc. 7.25% 15-AUG-2030 bond (PCT5917096 FINRA). It details the current coupon rate of 7.25% and indicates that the next interest payment is scheduled for August 17, 2026. The bond's market status is closed, with …

Cyclerion Therapeutics (Nasdaq:CYCN) - Stock Analysis

This Simply Wall St analysis provides an overview of Cyclerion Therapeutics (CYCN), highlighting its biopharmaceutical focus on sGC stimulators for CNS and peripheral diseases. The report details the company's financial health, significant risks including declining earnings forecasts and cash runway issues, and recent corporate …

PCT5917096 Bond Profile — Key Metrics

This article provides key metrics for the PCT5917096 bond issued by PureCycle Technologies, Inc. The convertible bond has a 7.25% coupon rate, an issue date of September 24, 2024, and a maturity date of August 15, 2030. PureCycle Technologies, Inc. specializes in recycling waste …

PureCycle settles lawsuit claiming misleading statements for $12M

PureCycle has agreed to settle a lawsuit alleging it made misleading statements for $12 million. The settlement resolves claims that the company disseminated false information. This news was reported by Jim Johnson on May 16, 2024.

Mitsui (TSE:8031) Could Be 28% Undervalued On Its Cleaner Energy Narrative

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Mitsui (TSE:8031) is back in focus after PureCycle Technologies, RM TOHCELLO and Mitsui reported progress on their recycled polypropylene partnership in Japan, moving …

Frontier tech research, news & data

This article provides an update on an insider transaction for BICYCLE THERAPEUTICS PLC (BCYC). A Form 3/4/5 filing was made on July 17, 2026, which can be viewed on SEC.gov. The article also mentions a "Power Delivery Gap Report" available from MLQ.ai, analyzing the …

Pure Cycle Q3 revenue rises 60% to $8.222M, net income $2.9M

Pure Cycle Corporation reported a 60% increase in Q3 revenue to $8.222 million and a 31% rise in net income to $2.9 million, driven by accelerated land development at Sky Ranch and higher water revenue from oil and gas demand. The company is ahead …

Bicycle Therapeutics (BCYC) grants 60,000 stock options to CSO

Bicycle Therapeutics plc's Chief Scientific Officer, Michael Skynner, was granted 60,000 employee stock options on July 15, 2026. These options allow for the purchase of Ordinary Shares at an exercise price of $4.21 per share and will vest over time, with one-fourth vesting on …

Bicycle Therapeutics (BCYC) awards 60,000 options to supply chain chief

Bicycle Therapeutics (BCYC) has granted its Chief Product and Supply Chain Officer, Michael Charles Ferguson Hannay, 60,000 employee stock options. The options have an exercise price of $4.21 per share and expire on July 15, 2036. The vesting schedule begins with one-fourth of the …

BICYCLE THERAPEUTICS PLC 4 — Jul 17, 2026 · MLQ

The article reports an insider transaction for Bicycle Therapeutics PLC, filed on July 17, 2026. It notes that the transaction details are available on SEC.gov, with the source document served from SEC EDGAR. The page also promotes a research report titled "The Power Delivery …

Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against Unicycive Therapeutics, Inc. following a stock drop. This investigation stems from the FDA issuing a second Complete Response Letter for Unicycive's kidney disease therapy, citing manufacturing deficiencies. The law firm is encouraging investors …

PureCycle Partners with RM TOHCELLO and Mitsui for Recycled BOPP Film Production - News and Statistics

PureCycle Technologies, RM TOHCELLO, and Mitsui & Co. have formed a strategic partnership to introduce recycled content into biaxially oriented polypropylene (BOPP) film, a material historically difficult to recycle to the purity levels required for packaging. Testing of PureCycle's PureFive resin has shown promising …

US' PureCycle, RM TOHCELLO partner on recycled BOPP packaging

PureCycle, Mitsui, and RM TOHCELLO have formed a strategic partnership to integrate recycled polypropylene into BOPP flexible packaging in Japan. They have completed successful pilot-scale runs using PureFive resin and are now preparing to introduce these materials to converters and brand owners. A commercial …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Unicycive Therapeutics, Inc. (UNCY) following a significant drop in its stock price. This investigation comes after the FDA issued a second Complete Response Letter for Unicycive's kidney disease therapy, oxylanthanum, citing unresolved third-party manufacturing …

PureCycle alliance targets 2027 launch for recycled BOPP films in Japan

PureCycle Technologies has partnered with RM TOHCELLO and Mitsui & Co. to introduce recycled polypropylene-based materials for BOPP films in Japan, with commercial availability expected in 2027. This collaboration aims to revolutionize the packaging sector by enabling the use of recycled content in flexible …

Japan BOPP Film Partnership Could Be A Game Changer For PureCycle Technologies (PCT)

PureCycle Technologies has partnered with RM TOHCELLO Co., Ltd. and Mitsui & Co., Ltd. to introduce high-purity recycled BOPP film in Japan, targeting a formal commercial agreement by 2027. This collaboration demonstrates PureCycle's dissolution recycling process for challenging polypropylene film applications, expanding end-market uses …

Price to sales forward of PureCycle Technologies, Inc. – NASDAQ:PCTTW

This article provides a brief snapshot of the "Price to sales forward" metric for PureCycle Technologies, Inc. (NASDAQ: PCTTW) on TradingView. It indicates that the market was closed with no trades recorded for this particular metric. The content seems to be a financial data …

Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group

Maxim Group analyst Jason McCarthy reiterated a Buy rating for Unicycive Therapeutics (UNCY) with a $30.00 price target, despite the company's recent quarterly GAAP net loss of $12.82 million. The Street maintains a Strong Buy consensus with an average price target of $36.71. Benchmark …

Cyclerion Therapeutics Inc. (CYCN) Q4 2025 Earnings: EPS Beat Driven by Disciplined Cost Management, Stock Declines - Dividend Earnings Report

Pure Cycle Spotlights Sky Ranch Cash Flows, Lowry Upside at Investor Day

Pure Cycle (NASDAQ: PCYO) recently highlighted the significant cash flow potential of its Sky Ranch development and the long-term growth prospects of its Lowry service area at an investor day. The company anticipates Sky Ranch residential units to generate $20 million to $30 million …

Cycurion Inc. (CYCU) Q1 2026 Earnings: Significant EPS Beat Drives Stock Rally - Pre-Earnings Setup

Cycurion Inc. (CYCU) Q1 2026 Earnings: Smaller-than-Expected Loss Drives Stock Higher - Revenue Breakdown Analysis